We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Molecular Markers Predict Disease Severity for RSV Infections

By LabMedica International staff writers
Posted on 26 Nov 2013
Profound systemic dysregulation of the immune response induced by respiratory syncytial virus (RSV) infection in young children indicates that molecular markers might be able to predict disease severity.

RSV is the leading cause of viral lower respiratory tract infection (LRTI) and hospitalization in infants and because of the incomplete understanding of the disease pathogenesis, there is no licensed vaccine, and treatment remains symptomatic.

Scientists at the Nationwide Children's Hospital (Columbus, OH, USA) and their colleagues examined the global gene expression patterns in blood samples from four different cohorts of children who were hospitalized with lower respiratory tract infections. More...
Whole blood ribonucleic acid (RNA) was processed and hybridized into Human WG-6 v3 or Human HT-12 v4 beadchips and scanned on the Beadstation 500 system (Illumina; San Diego, CA, USA).

They found that children who are ill with RSV infections have a characteristic gene expression pattern that is different, not only from healthy children but also from children infected with either influenza virus or human rhinovirus, two other common causes of lower respiratory tract disease. This pattern, which the scientists called the RSV biosignature, could reliably identify children with RSV infections in different settings. From it, they derived a genomic severity score that correlated with clinical indices of disease severity, with length of hospitalization, and the need for supplemental oxygen.

The RSV biosignature also provided insights into the status of the immune system in the sick children. RSV infection was associated with elevated levels of some inflammation genes as well as suppression of nonspecific immune system genes and reduced expression of specific B and T cell genes. This was particularly evident in infants under six months of age.

The authors concluded that blood RNA profiles of infants with RSV lower respiratory tract infections allow specific diagnosis, better understanding of disease pathogenesis, and assessment of disease severity, and they add, their study opens new avenues for biomarker discovery and identification of potential therapeutic or preventive targets. The study was published on November 12, 2013, in the journal Public Library of Science Medicine.

Related Links:

Nationwide Children's Hospital
Illumina 



Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Automatic CLIA Analyzer
Shine i9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.